Loïck Vidot

538 total citations · 1 hit paper
13 papers, 273 citations indexed

About

Loïck Vidot is a scholar working on Oncology, Pathology and Forensic Medicine and Economics and Econometrics. According to data from OpenAlex, Loïck Vidot has authored 13 papers receiving a total of 273 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 4 papers in Pathology and Forensic Medicine and 3 papers in Economics and Econometrics. Recurrent topics in Loïck Vidot's work include Colorectal Cancer Treatments and Studies (12 papers), Cancer Treatment and Pharmacology (8 papers) and Genetic factors in colorectal cancer (4 papers). Loïck Vidot is often cited by papers focused on Colorectal Cancer Treatments and Studies (12 papers), Cancer Treatment and Pharmacology (8 papers) and Genetic factors in colorectal cancer (4 papers). Loïck Vidot collaborates with scholars based in France, Italy and Poland. Loïck Vidot's co-authors include Eric Van Cutsem, Julien Taı̈eb, Lucjan Wyrwicz, Josep Tabernero, Chiara Cremolini, Gerald W. Prager, Élena Elez, Dominik Paul Modest, Karim A. Benhadji and Igor Bondarenko and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Loïck Vidot

12 papers receiving 270 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

2023 183 citations Gerald W. Prager, Julien Taı̈eb et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Loïck Vidot France	5	224	85	78	37	29	13	273
Catherine Leger France	5	216 1.0×	77 0.9×	96 1.2×	39 1.1×	33 1.1×	10	263
Pierre-Guillaume Poureau France	5	219 1.0×	72 0.8×	93 1.2×	40 1.1×	33 1.1×	12	272
Erica N. Heying United States	6	223 1.0×	92 1.1×	86 1.1×	24 0.6×	42 1.4×	10	285
Merete Krogh Denmark	6	195 0.9×	43 0.5×	70 0.9×	32 0.9×	21 0.7×	17	233
Patrick Texereau France	8	221 1.0×	50 0.6×	93 1.2×	25 0.7×	40 1.4×	15	280
Thomas Göhler Germany	10	132 0.6×	28 0.3×	67 0.9×	39 1.1×	56 1.9×	34	225
Francesca Daniel Italy	7	123 0.5×	59 0.7×	56 0.7×	29 0.8×	68 2.3×	21	180
Dong Ma China	5	193 0.9×	58 0.7×	78 1.0×	63 1.7×	26 0.9×	13	284
Juan José Reina Spain	6	280 1.3×	51 0.6×	90 1.2×	29 0.8×	14 0.5×	8	324
Bruce Colwell Canada	8	145 0.6×	34 0.4×	37 0.5×	15 0.4×	18 0.6×	17	180

Countries citing papers authored by Loïck Vidot

Since Specialization

Citations

This map shows the geographic impact of Loïck Vidot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Loïck Vidot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Loïck Vidot more than expected).

Fields of papers citing papers by Loïck Vidot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Loïck Vidot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Loïck Vidot. The network helps show where Loïck Vidot may publish in the future.

Co-authorship network of co-authors of Loïck Vidot

This figure shows the co-authorship network connecting the top 25 collaborators of Loïck Vidot. A scholar is included among the top collaborators of Loïck Vidot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Loïck Vidot. Loïck Vidot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Fougeray, Ronan, et al.. (2024). Futility Interim Analysis Based on Probability of Success Using a Surrogate Endpoint. Pharmaceutical Statistics. 23(6). 971–983.

Wyrwicz, Lucjan, Julien Taı̈eb, Timothy Price, et al.. (2023). Clinical and quality of life outcomes with trifluridine/tipiracil: PRECONNECT and TALLISUR studies. 12(3). 1 indexed citations

Taı̈eb, Julien, et al.. (2023). Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: final results from the phase IIIb single-arm PRECONNECT study by duration of therapy. BMC Cancer. 23(1). 94–94. 11 indexed citations

Prager, Gerald W., Julien Taı̈eb, Marwan Fakih, et al.. (2023). Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. New England Journal of Medicine. 388(18). 1657–1667. 183 indexed citations breakdown →

Özet, Ahmet, Faysal Dane, Nuri Faruk Aykan, et al.. (2022). Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey. Future Oncology. 18(29). 3267–3276. 2 indexed citations

Wyrwicz, Lucjan, Jean‐Baptiste Bachet, Meinolf Karthaus, et al.. (2022). SO-18 Reinforcing clinical outcomes with patient-reported QoL outcomes in patients with mCRC receiving FTD/TPI: Pooled analysis of PRECONNECT and TALLISUR studies. Annals of Oncology. 33. S364–S364. 2 indexed citations

Mello, Celso Abdon Lopes de, Felipe Melo Cruz, Fernando Meton de Alencar Câmara Vieira, et al.. (2022). Brazilian cohort results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer. SHILAP Revista de lepidopterología. 18(CP). 1 indexed citations

Taı̈eb, Julien, et al.. (2021). SO-18 Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: Final results according to duration of treatment from the phase IIIb, international, open-label, early-access PRECONNECT study. Annals of Oncology. 32. S210–S210. 2 indexed citations

Bachet, Jean‐Baptiste, Lucjan Wyrwicz, Timothy Price, et al.. (2020). Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study. ESMO Open. 5(3). e000698–e000698. 31 indexed citations

10.

Tabernero, Josep, Guillem Argilés, Alberto F. Sobrero, et al.. (2020). Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis. ESMO Open. 5(4). e000752–e000752. 29 indexed citations

11.

Argilés, Guillem, Josep Tabernero, Alberto F. Sobrero, et al.. (2019). Exploratory analysis of the effect of FTD/TPI in mCRC patients treated in RECOURSE by different prognostic factors: impact on ECOG PS. Annals of Oncology. 30. iv117–iv117. 1 indexed citations

12.

Taı̈eb, Julien, Timothy Price, Fortunato Ciardiello, et al.. (2019). Health-related quality of life in the early-access phase IIIb study of trifluridine/tipiracil in pretreated metastatic colorectal cancer (mCRC): Results from PRECONNECT study.. Journal of Clinical Oncology. 37(4_suppl). 638–638. 3 indexed citations

13.

Tabernero, Josep, Alberto Sobrero, Christophe Borg, et al.. (2019). Exploratory analysis of the effect of FTD/TPI in patients treated in RECOURSE by prognostic factors.. Journal of Clinical Oncology. 37(4_suppl). 677–677. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact